BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Belyaev NN, Abdolla N, Perfilyeva YV, Ostapchuk YO, Krasnoshtanov VK, Kali A, Tleulieva R. Daunorubicin conjugated with alpha-fetoprotein selectively eliminates myeloid-derived suppressor cells (MDSCs) and inhibits experimental tumor growth. Cancer Immunol Immunother 2018;67:101-11. [DOI: 10.1007/s00262-017-2067-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Zhou J, Shen Q, Lin H, Hu L, Li G, Zhang X. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment. J Cancer Res Clin Oncol 2019;145:329-36. [PMID: 30426212 DOI: 10.1007/s00432-018-2790-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
2 Pak VN. The possible drug for cancer and metastasis prevention. Future Drug Discovery. [DOI: 10.4155/fdd-2022-0008] [Reference Citation Analysis]
3 Pak VN. α-fetoprotein-binding toxins and teratogens against cancer. Ther Deliv 2019;10:1-3. [PMID: 30730821 DOI: 10.4155/tde-2018-0068] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Pak VN. Selective targeting of myeloid-derived suppressor cells in cancer patients through AFP-binding receptors. Future Sci OA 2019;5:FSO321. [PMID: 30652015 DOI: 10.4155/fsoa-2018-0029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang Y, Ding Y, Deng Y, Zheng Y, Wang S. Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer. J Immunother Cancer 2020;8:e000609. [PMID: 33051339 DOI: 10.1136/jitc-2020-000609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
6 Lin B, Dong X, Wang Q, Li W, Zhu M, Li M. AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers. Front Cell Dev Biol 2021;9:635476. [PMID: 33898423 DOI: 10.3389/fcell.2021.635476] [Reference Citation Analysis]
7 Lee JM, Shin KS, Koh CH, Song B, Jeon I, Park MH, Kim BS, Chung Y, Kang CY. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells. Cancer Lett 2021;520:38-47. [PMID: 34224797 DOI: 10.1016/j.canlet.2021.06.031] [Reference Citation Analysis]
8 Tarantini F, Cumbo C, Anelli L, Zagaria A, Specchia G, Musto P, Albano F. Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia? Cancers (Basel) 2021;13:4121. [PMID: 34439275 DOI: 10.3390/cancers13164121] [Reference Citation Analysis]
9 Gulevskyy OK; Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv. URRENT CONCEPT OF THE STRUCTURAL AND FUNCTIONAL PROPERTIES OF ALFA-FETOPROTEIN AND THE POSSIBILITIES OF ITS CLINICAL APPLICATION. Biotechnol acta 2021;14:25-37. [DOI: 10.15407/biotech14.01.025] [Reference Citation Analysis]
10 De La Fuente A, Zilio S, Caroli J, Van Simaeys D, Mazza EMC, Ince TA, Bronte V, Bicciato S, Weed DT, Serafini P. Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy. Sci Transl Med 2020;12:eaav9760. [PMID: 32554710 DOI: 10.1126/scitranslmed.aav9760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]